Close this search box.

Prostate Cancer Advanced Imaging: Unlocking the Potential

September 19, 2023

If you are unable to access ON24, click here.

Prostate cancer is the most common cancer and the second leading cause of cancer death in men. Over the past decade, there have been significant advancements in imaging assessment and treatment of prostate cancer. The introduction of PSMA PET-CT has greatly improved the detection of loco-regional and metastatic cancer.

During the webinar, we will explore the utilization of PSMA-PET and MRI for the diagnosis and treatment of prostate cancer. We will also have an expert radiologist and radiation oncologist demonstrate contouring using Accuray Precision® Treatment Planning for various cases and discuss their processes, the challenges that may arise and how to resolve them.

John Melnick, M.D.

Medical Director, Lenox Hill Radiology & Medical Imaging Associates P.C., NY

Dr. John Melnick is a board-certified radiologist with a special interest in body imaging and a focus on oncology. He earned his medical degree at Mount Sinai School of Medicine (NYC) and completed his residency at North Shore University Hospital (NY). He completed his fellowship at Massachusetts General Hospital (Boston). Dr. Melnick began his career in radiology in 1999 and in 2009, he became part of the Lenox Hill Radiology team.

Dr. Melnick first became interested in radiology during medical school while studying cardiac imaging. His focus on cancer care began during his training at Massachusetts General Hospital. “I was exposed to some of the early research on prostate cancer imaging,” he recalls. “With this background, I have become increasingly involved in prostate care and providing an imaging-based resource for many prostate cancer care providers within New York City.”

Jonathan W. Lischalk, M.D.

Medical Director of NYCyberKnife, Perlmutter Cancer Center—Manhattan, NY

Dr. Jonathan W. Lischalk is the Medical Director of NYCyberKnife at Perlmutter Cancer Center in Manhattan, NY. As a specialist in managing prostate, lung, brain, and spine cancer using the CyberKnife® System, Dr. Lischalk enjoys working collaboratively with doctors from different specialties such as radiology, pathology, surgery, and medical oncology to achieve the best outcomes for his patients.

In addition to his role as Medical Director, Dr. Lischalk serves as an assistant professor and director of research for the Department of Radiation Oncology at NYU Long Island School of Medicine. This gives his patients access to the latest clinical trials and advanced treatment options. Dr. Lischalk has authored almost 40 peer-reviewed medical publications, is a member of the American Society for Radiation Oncology, the American Society of Clinical Oncology, and the American Board of Radiology. He has also served as the president of the American College of Radiation Oncology Resident Committee and was recognized as one of Washingtonian’s “2020 Top Doctors.”